19:25 , Apr 27, 2018 |  BC Week In Review  |  Clinical News

VenatoRx reports preclinical data for VNRX-5133 plus cefepime

VenatoRx Pharmaceuticals Inc. (Malvern, Pa.) reported preclinical data from a mouse model of cephalosporin-resistant Klebsiella pneumoniae lung infection showing that VNRX-5133 plus the cephalosporin antibiotic cefepime led to greater reductions in mean bacterial lung titers...
17:29 , Jan 12, 2018 |  BC Week In Review  |  Clinical News

Achaogen reports Phase I data for antibacterial candidate C-Scape

Achaogen Inc. (NASDAQ:AKAO) reported top-line data from a Phase I in 41 healthy volunteers with and without renal impairment showing that antibacterial candidate C-Scape for 14 days was well tolerated with no serious adverse events...
23:20 , Nov 30, 2017 |  BC Week In Review  |  Clinical News

Allergan's Avycaz gets Priority Review

In October, FDA accepted and granted Priority Review to an sNDA from Allergan plc (NYSE:AGN) for Avycaz ceftazidime/avibactam (CAZ-104) to treat hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) in adults. FDA's decision is...
18:55 , Oct 27, 2017 |  BC Week In Review  |  Company News

NIH, Geom to conduct Phase I of GT-1

NIH's National Institute of Allergy and Infectious Diseases (NIAID) and Geom Therapeutics Inc. (San Diego, Calif.) partnered to conduct a Phase I trial of Geom's lead candidate GT-1 (LCB10-0200). The double-blind, placebo-controlled, dose-escalation study will...
21:40 , Sep 29, 2017 |  BC Week In Review  |  Company News

Basilea grants China Resources Holdings rights to Zevtera in China

Basilea Pharmaceutica Ltd. (SIX:BSLN) granted the Shenzhen China Resources Gosun Pharmaceutical Co. Ltd. unit of China Resources Holding Co. Ltd. (Wanchai, China) exclusive rights to develop and commercialize antibiotic Zevtera ceftobiprole in China, including Hong...
19:11 , Sep 8, 2017 |  BioCentury  |  Finance

Antibiotic engine

A combination of non-dilutive funding and a newly-raised $31.9 million series B-1 round should give Entasis Therapeutics Inc. enough cash to see its lead candidate all the way through commercialization and to move two others...
14:36 , Apr 28, 2017 |  BC Week In Review  |  Clinical News

Zavicefta: Additional Ph III REPROVE data

Additional data from the double-blind, double-dummy, international Phase III REPROVE trial in 879 patients with HAP, including VAP, showed that 2,000 mg/500 mg IV Zavicefta ceftazidime/avibactam as a 2-hour infusion every 8 hours led to...
19:14 , Mar 17, 2017 |  BC Week In Review  |  Company News

Zavicefta sales and marketing update

Pfizer launched Zavicefta ceftazidime/avibactam in the U.K. and Germany to treat complicated infections caused by Gram-negative bacteria. Pfizer said the cost of Zavicefta is £857 ($1,047) for 10 vials. Zavicefta is indicated to treat complicated intra-abdominal...
00:01 , Feb 3, 2017 |  BC Week In Review  |  Clinical News

Avycaz regulatory update

FDA approved an sNDA from Allergan for Avycaz ceftazidime/avibactam to include data from the Phase III RECAPTURE and REPRISE trials of the drug to treat complicated urinary tract infections (cUTIs) caused by susceptible Gram-negative bacteria....
20:32 , Jan 13, 2017 |  BC Week In Review  |  Clinical News

Cefiderocol: Ph II APEKs-cUTI data

Top-line data from 371 hospitalized adult patients with Gram-negative cUTI with or without pyelonephritis in the microbiological intent-to-treat (mITT) population of the double-blind, international Phase II APEKs-cUTI trial showed that 2 g IV cefiderocol every...